Exicure Inc (XCUR)

Exicure, Inc. Reports Third Quarter 2023 Financial Results - Business Wire

Business Wire

NewAmsterdam Pharma (NASDAQ:NAMS) and Exicure (NASDAQ:XCUR) Financial Review - Defense World

Defense World

Earnings Preview: Exicure, Inc. (XCUR) Q3 Earnings Expected to Decline - Yahoo Singapore News

Yahoo Singapore News

Exicure, Inc. (XCUR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo New Zealand News

Yahoo New Zealand News

Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

Benzinga

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the ... - Business Wire

Business Wire

Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket

Benzinga

Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Why Aehr Test Systems Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Aehr Test Systems Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket - Markets Insider

Markets Insider

Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

US Stocks Down; Nonfarm Payrolls Rise By 199,000 In November

Benzinga

Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Is Exicure (XCUR) Stock Up 57% Today? - InvestorPlace

InvestorPlace

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire

Business Wire

Exicure Appoints Paul Kang As CEO - citybiz

citybiz

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update - Business Wire

Business Wire

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld - Business Wire

Business Wire

3 Nano-Cap Penny Stocks to Buy for Explosive Gains in 2023 - InvestorPlace

InvestorPlace

Exicure continues death spiral, putting transaction of some kind on the table - Fierce Biotech

Fierce Biotech

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of ... - Business Wire

Business Wire

Following $685 million-plus licensing agreement, Ann Arbor-based Evoq replaces CEO - Crain's Detroit Business

Crain's Detroit Business

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements - Business Wire

Business Wire

Exicure Lays off Two-Thirds of Workforce, Suspends R&D in Restructuring - BioSpace

BioSpace

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces ... - Business Wire

Business Wire

eExicure XCUR Stock Price is up, can it go higher? URGENT REPORT - Small Cap Exclusive

Small Cap Exclusive

XCUR Stock Price is liquid, can it go higher? URGENT REPORT - Small Cap Exclusive

Small Cap Exclusive

EXICURE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been ... - Business Wire

Business Wire

Exicure hires new CEO after Brian Bock leaves after only two months - The Business Journals

The Business Journals

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Exicure, Inc. with Losses of $100,000 to ... - AccessWire

AccessWire

Exicure Winds Down XCUR-FXN Program for Friedreich's Ataxia - Friedreich's Ataxia News

Friedreich's Ataxia News

Bill Gates Slashes Investment in This Penny Biotech Stock - Barron's

Barron's

Ipsen and Exicure to develop therapies for neurodegenerative disorders - Pharmaceutical Technology

Pharmaceutical Technology

Ipsen puts down $20M in $1B deal with Exicure for rare neuro disorders - Fierce Biotech

Fierce Biotech

Revisiting The Investment Thesis On Exicure (NASDAQ:XCUR) - Seeking Alpha

Seeking Alpha

Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through ... - Business Wire

Business Wire

Skender completes first biotech lab space and base-building work for Sterling Bay's life sciences project – REJournals - REjournals.com

REjournals.com

Allergan pays Exicure $25M to discover nucleic acid hair loss drugs - Fierce Biotech

Fierce Biotech

Exicure Announces License and Development Agreement with Dermelix Biotherapeutics in Rare Genetic Skin Diseases - Business Wire

Business Wire

Exicure CEO Giljohann develops breakthrough ‘spherical nucleic acid - Crain's Chicago Business

Crain's Chicago Business

Purdue Pharma and Exicure Announce Strategic Research Collaboration Agreement to Discover and Develop a ... - Business Wire

Business Wire